<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337268</url>
  </required_header>
  <id_info>
    <org_study_id>H-18050603</org_study_id>
    <nct_id>NCT04337268</nct_id>
  </id_info>
  <brief_title>Acute Effects of GLP-1 on Renal Hemodynamics</brief_title>
  <acronym>GLP1RRBF</acronym>
  <official_title>Acute Effects of GLP-1 on Renal Hemodynamics: Simultaneous Perfusion and Oxygenation Measurements in Cortex and Medulla Using Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Cardiovascular and Renal Research, University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the hypothesis, that GLP-1's suppression of ANG II and natriuretic
      action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue
      oxygenation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human studies have recently demonstrated a significant natriuretic effect of GLP-1 when the
      extracellular fluid volume (ECFV) is expanded by intravenous sodium-loading; in these
      studies, there was a suppression of ANG II with no change in net renal hemodynamics, pointing
      to a tubular mechanism for reduced NaCl reabsorption secondary to the ANG II suppression. In
      the current randomized and controlled study, investigators aim to test the hypothesis that
      GLP-1's suppression of ANG II and natriuretic action increase medullary perfusion and
      decrease oxygen consumption, leading to higher tissue oxygenation. Thus, contributing to the
      renoprotective action of GLP-1.

      Under fixed sodium intake for 4 days before each study day, 10 healthy male participants will
      be investigated during a 1-hour infusion of GLP-1 (1.5 pmol/kg/min) or vehicle together with
      an intravenous infusion of 0.9% NaCl. Interleaved measurements of RAF, oxygenation (T2*) and
      perfusion by arterial spin labeling in the renal cortex and medulla at fixed time points will
      be conducted, using Magnetic Resonance Imaging (MRI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T2* signal</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes in T2* signal in renal cortex and medulla</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Spin Labeled (ASL)</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes in Arterial Spin Labeled (ASL) MRI Perfusion Imaging in renal cortex and medulla</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Artery Flow Phase (RAF)</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes in Renal Artery Flow Phase (RAF)-Contrast Magnetic Resonance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>The GLP-1-mediated Gut-kidney Axis</condition>
  <arm_group>
    <arm_group_label>human glucagon-like peptide-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention:
Drug: human glucagon-like peptide-1 Other names: GLP-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention:
Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-Like Peptide 1</intervention_name>
    <description>Intravenous infusion (1.5 pmol/kg/min) for 60 min.</description>
    <arm_group_label>human glucagon-like peptide-1</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline 0.9%</intervention_name>
    <description>Intravenous infusion for 60 min.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for GLP-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal health demonstrated by medical examination.

          -  Normal values for fasting plasma glucose, total cholesterol, triglyceride, HDL, LDL,
             creatinine, AST, ALT and electrolyte concentrations.

        Exclusion Criteria:

          -  Immunosuppressive treatment for the previous 12 months.

          -  Alcohol abuse.

          -  Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4)
             inhibitors, or GLP-1 receptor agonists that, in the opinion of the investigator, may
             interfere with glucose metabolism.

          -  Use of lithium.

          -  Medical treatment that affects insulin secretion or cardiovascular efficacy goals.

          -  Liver disease (ALT&gt; 2 x normal value).

          -  Renal impairment (creatinine&gt; 130 µM and / or albuminuria).

          -  Severe claustrophobia.

          -  MRI incompatible foreign bodies.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Asmar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet - Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. Review.</citation>
    <PMID>17928588</PMID>
  </reference>
  <reference>
    <citation>Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007 May;48(5):736-43.</citation>
    <PMID>17475961</PMID>
  </reference>
  <reference>
    <citation>Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014 Apr;155(4):1280-90. doi: 10.1210/en.2013-1934. Epub 2014 Jan 27.</citation>
    <PMID>24467746</PMID>
  </reference>
  <reference>
    <citation>Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, Moro C, Jonassen T, Bülow J. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab. 2015 Apr 15;308(8):E641-9. doi: 10.1152/ajpendo.00429.2014. Epub 2015 Feb 10.</citation>
    <PMID>25670826</PMID>
  </reference>
  <reference>
    <citation>Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, Moro C, Sorensen CM, Jonassen T, Bülow J. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am J Physiol Endocrinol Metab. 2016 May 1;310(9):E744-53. doi: 10.1152/ajpendo.00518.2015. Epub 2016 Mar 8.</citation>
    <PMID>26956188</PMID>
  </reference>
  <reference>
    <citation>Asmar A, Asmar M, Simonsen L, Madsbad S, Holst JJ, Hartmann B, Sorensen CM, Bülow J. Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. Physiol Rep. 2017 Feb;5(3). pii: e13073. doi: 10.14814/phy2.13073.</citation>
    <PMID>28174344</PMID>
  </reference>
  <reference>
    <citation>Skov J, Dejgaard A, Frøkiær J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013 Apr;98(4):E664-71. doi: 10.1210/jc.2012-3855. Epub 2013 Mar 5.</citation>
    <PMID>23463656</PMID>
  </reference>
  <reference>
    <citation>Asmar A, Cramon PK, Simonsen L, Asmar M, Sorensen CM, Madsbad S, Moro C, Hartmann B, Jensen BL, Holst JJ, Bülow J. Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2509-2519. doi: 10.1210/jc.2019-00004.</citation>
    <PMID>30835273</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ali Asmar</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>glucagon-like peptide-1</keyword>
  <keyword>kidney</keyword>
  <keyword>renal hemodynamics</keyword>
  <keyword>renal blood flow</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

